Novartis stock sinks toward worst day ever after third drug trial failure in a week Sep 08, 2026 · Cris Tolomia The HARBOR study failure is Novartis's second major late-stage trial setback in days and its third pipeline blow in a week Read more »
.png?branch=production)
![Prediction: This Pipeline Stock's Payout Will Grow Faster Than Chevron's [or Exxon's] Over the Next 5 Years](https://media.zenfs.com/en/motleyfool.com/ce9f8ee3e848bda8f77a44da7292e1e4.jpg)
